Food Allergy Drug Pipeline Analysis Report 2025

Food allergy is an immune system reaction to certain foods, potentially causing severe, life-threatening symptoms. It affects around 220 million people globally, with a significant unmet need for effective treatments beyond avoidance strategies and emergency epinephrine. Current therapeutic options remain limited, driving research into innovative drugs and therapeutics. Emerging drug candidates, including biologics targeting immune modulation, show promise in enhancing patient outcomes. This evolving landscape highlights the potential for more effective food allergy therapeutic products in the coming years.

Report Coverage

The Food Allergy Drug Pipeline Insight Report by the publisher gives comprehensive insights into food allergy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for food allergy. The food allergy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The food allergy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with food allergy treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to food allergy.

Food Allergy Drug Pipeline Outlook

Food allergy is an immune system reaction to certain foods, triggering symptoms like hives, swelling, digestive issues, or even anaphylaxis. It occurs when the body mistakenly identifies a harmless food as a threat. Common allergens include peanuts, tree nuts, milk, eggs, soy, wheat, fish, and shellfish.

Food allergy management focuses on allergen avoidance and symptom control. Antihistamines can relieve mild reactions, while epinephrine is essential for anaphylaxis. Oral immunotherapy is an emerging treatment to build tolerance to allergens. Regular consultations with an allergist, accurate food labeling checks, and carrying emergency medication are vital steps to ensure safety and prevent severe allergic reactions.

Food Allergy Epidemiology

Food allergy affects approximately 220 million people globally, with significant regional variations. In the United States, it impacts up to 8% of children and 10% of adults. In the United Kingdom, 6% of adults, or 2.4 million individuals, have clinically confirmed food allergies. In Japan, prevalence rates reach 10% in infants, 5% in young children, and 4.5% in school children.

Food Allergy - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of food allergy drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Monoclonal Antibodies
• Biologics
• Small Molecules
• Peptides
• Immunotherapies
• Others

By Route of Administration

• Oral
• Parenteral
• Others

Food Allergy - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total food allergy clinical trials.

Food Allergy - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the food allergy pipeline analysis include monoclonal antibodies, biologics, small molecules, peptides, immunotherapies, and others. The food allergy report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for food allergy.

Food Allergy Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the food allergy drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed food allergy therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in food allergy clinical trials:

• Novartis Pharmaceuticals
• Regeneron Pharmaceuticals
• DBV Technologies
• Allergy Therapeutics
• IgGenix Australia Pty Ltd.
• InnoUp Farma S.L.
• Aravax Pty Ltd.
• Vedanta Biosciences, Inc.
• Parexel
• Genentech

Food Allergy Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for food allergy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of food allergy drug candidates.

Drug: Ligelizumab

Ligelizumab, sponsored by Novartis Pharmaceuticals, is undergoing a Phase III extension study to evaluate its long-term safety and efficacy in food allergy treatment. This next-generation anti-IgE monoclonal antibody blocks the IgE/FceRI pathway, reducing allergic inflammation. The study will assess symptom resolution, quality of life improvements, and the drug’s potential for long-term, self-administered treatment.

Drug: Remibrutinib

Remibrutinib, an oral BTK inhibitor, aims to reduce allergic reactions by modulating immune responses. Novartis Pharmaceuticals is conducting a Phase II study to evaluate the efficacy, safety, and tolerability of Remibrutinib in adults with peanut allergies. The study will assess participants' ability to tolerate increasing peanut protein doses after one month of treatment with varying drug doses.

Drug: IGNX001

IGNX001 is an IgG4 monoclonal antibody developed by IgGenix Australia Pty Ltd. It is currently undergoing a Phase I clinical trial for peanut allergy. The study aims to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics. IGNX001 has demonstrated potent inhibition of peanut-induced mast cell degranulation, positioning it as a promising food allergy therapeutic product for improved allergy management.

Reasons To Buy This Report

The Food Allergy Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for food allergy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into food allergy collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Food Allergy - Pipeline Insight Report

• Which companies/institutions are leading the food allergy drug development?
• What is the efficacy and safety profile of food allergy pipeline drugs?
• Which company is leading the food allergy pipeline development activities?
• What is the current food allergy commercial assessment?
• What are the opportunities and challenges present in the food allergy drug pipeline landscape?
• What is the efficacy and safety profile of food allergy pipeline drugs?
• Which company is conducting major trials for food allergy drugs?
• Which companies/institutions are involved in food allergy collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in food allergy?

This product will be delivered within 3-5 business days.